Printer Friendly

Federal MicroArray Quality Control Study Addresses Intercompatability of Microarray Gene Expression Platforms; Results Pave the Way for Researchers to Choose Platform Based on Performance, Value, Ease of.

SAN DIEGO -- First graph, correct url should read: (sted

The corrected release reads:


The FDA-led MicroArray Quality Control (MAQC) project findings announced today ( show that microarray gene expression data from the commercial platforms tested in the study show high degrees of correlation. The results, published in the peer-reviewed journal Nature Biotechnology, indicates that scientists have the ability to choose a gene expression platform based on value, ease of use and quality of content, with little to no legacy data concerns.

The MAQC project successfully compared multiple whole-genome gene expression profiles across various commercial platforms at an unprecedented scale. It showed that there was a relatively high level of agreement between all platforms as well concordance with reverse transcription PCR technology, a separate technique for measuring differential gene expression, confirming that microarray data is directly comparable, accurate and biologically significant.

"The MAQC project observed intraplatform reproducibility across test sites as well as high interplatform concordance in terms of genes identified as differentially expressed," said Leming Shi, MAQC project director at the U.S. Food and Drug Administration's National Center for Toxicological Research. "One major result was that platforms with divergent approaches often generated comparable results of differential gene expression. In other words, the differential gene expression patterns generated were reflective of biology regardless of the difference in technology platforms."

"Given such high levels of concordance, choosing a gene expression platform should primarily be driven by such factors as cost, ease of use and quality of content," said Shawn Baker, Illumina's gene expression scientific product manager. "Illumina's BeadChips, which were shown to consistently be among the very best performers across the various technical measurements assessed by the MAQC, are also substantially less expensive than all other commercial whole-genome arrays used in the study. With array and reagent costs less than half that of other commercial arrays, the use of Illumina BeadChips allows for experimental designs to be expanded, yielding more powerful and farther-reaching results with the same research budget."

The MAQC results pave the way for microarray researchers to tackle the legacy data issue. Until now, researchers have hesitated to use the latest microarray gene expression technology due to concerns around inconsistent data when comparing new findings against research derived from older or different microarray technology. Similar results have been validated elsewhere ( Illumina is working with industry leaders to develop tools that will facilitate migration of legacy data to its gene expression platform.

The MAQC project was established to generate a set of quality control tools and standards for the microarray research community and advance pharmacogenomics and bioinformatics for more effective medicines and medical products. The project involved 137 participants representing 51 organizations, including the FDA, NIH, EPA and USDA, all major whole-genome gene expression platform providers including Illumina as well as several alternative gene expression platform providers. MAQC included validated reference samples, a large collection of multiplatform reference datasets as well as analysis tools. As a MAQC project participant, Illumina has posted its gene expression data at

For more information on this project, visit the MAQC website: tm

About Illumina

Illumina (Nasdaq:ILMN) ( develops and markets next-generation tools for the large-scale analysis of genetic variation and function. The Company's proprietary BeadArray technology -- used in leading genomics centers around the world -- provides the throughput, cost effectiveness and flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will help pave the way to personalized medicine by correlating genetic variation and gene function with particular disease states, enhancing drug discovery, allowing diseases to be detected earlier and more specifically, and permitting better choices of drugs for individual patients.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are the costs and outcome of Illumina's litigation with Affymetrix, the Company's ability to scale and integrate CyVera technology, the ability to further scale oligo synthesis output and technology to satisfy market demand deriving from the Company's collaboration with Invitrogen, Illumina's ability to further develop and commercialize its BeadArray technologies and to deploy new gene expression and genotyping products and applications for its platform technology, to manufacture robust Sentrix(R) arrays -- including HumanHap BeadChips -- and Oligator(R) oligonucleotides, and other factors detailed in the Company's filings with the Securities and Exchange Commission including its recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina disclaims any intent or obligation to update these forward-looking statements beyond the date of this release.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 8, 2006
Previous Article:Symphogen to Present Corporate Update at Bear Stearns Healthcare Conference.
Next Article:Alliant Insurance Services Announces Agreement to Acquire U.S. Retail Operations of Jardine Lloyd Thompson Group.

Related Articles
Toxicogenomics: roadblocks and new directions. (Standards).
FDA eyes pharmacogenomics data.
Microarrays demystified.
Identification of platform-independent gene expression markers of cisplatin nephrotoxicity.
Gene activity predicts leukemia outcome.
Drawing comparisons at Duke.
From point B to point A: applying toxicogenomics to biological inference.
Toxicogenomics data: the road to acceptance.
Workgroup report: review of genomics data based on experience with mock submissions--view of the CDER pharmacology toxicology Nonclinical...

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters